FIDSON ended the first half of its 2022 financial year on a strong footing, recording a 57.62% YoY expansion in its topline to NGN20.38bn (vs. NGN12.93bn in H1:2021). Product innovation, increased prices and extended distribution channels across its business lines contributed to the growth witnessed; Ethical (+69.07%), Over the Counter (24.87%), and Consumer Healthcare
(+1944.62%).
